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Abstract: Poly(adenosine diphosphate-ribose) polymerase (PARP) 
inhibitors have shown promising clinical activity in epithelial ovar-
ian cancer. Following the observation in vitro that PARP inhibition 
is synthetically lethal in tumors with BRCA mutations, PARP inhibi-
tion has become the first genotype-directed therapy for BRCA1- 
and BRCA2-associated ovarian cancer. However, it is becoming 
clear that PARP inhibition also may have clinical utility in cancers 
associated with defects or aberrations in DNA repair that are 
unrelated to BRCA mutations. Deficient DNA repair mechanisms 
are present in approximately 30% to 50% of high-grade serous 
ovarian cancers, the most common histologic subtype. Olaparib is 
the best-studied PARP inhibitor to date, and a number of phase 3 
trials with this agent are underway. This article reviews the devel-
opment of olaparib for ovarian cancer and discusses the current 
evidence for its use, ongoing studies, future research directions, 
and the challenges ahead. 
Introduction
Ovarian cancer is the most lethal gynecologic malignancy and 
the fifth-leading cause of cancer-related deaths in women.1 The 
absence of a validated screening program and the nonspecificity 
of early disease symptoms mean that most women are diagnosed 
at an advanced stage. The 5-year survival rate is approximately 
30%.1 The current standard of care consists of aggressive cytore-
ductive surgery to remove all visible disease, plus platinum- and 
taxane-based chemotherapy.2,3 Despite a high initial response rate 
to chemotherapy, most women with advanced ovarian cancer 
eventually will have a recurrence; median progression-free survival 
(PFS) is just 18 months from diagnosis.4 Although the majority 
of patients will respond again to platinum-based chemotherapy, 
sensitivity decreases with each subsequent relapse. The disease 
inevitably becomes resistant or refractory to platinum agents, and 
is ultimately fatal.5 In order to advance the management of ovarian 
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cancer, new agents are required that improve the rate of 
durable remission and/or have activity against chemore-
sistant disease.
The treatment of cancer has changed dramatically 
over the last decade. Intensive research has increased 
our understanding of many of the cellular functions 
that go awry in cancer development and progression. 
Furthermore, the advent of next-generation sequencing 
has provided detailed information on the cancer genome 
for many cancer types. This understanding offers the 
prospect of targeting molecular alterations and path-
ways directly to develop more effective cancer therapy. 
High-grade serous ovarian cancer, the most common 
subtype of epithelial ovarian cancer, is characterized by 
almost ubiquitous TP53 (96%) mutations and a high 
frequency of mutations in BRCA1 (12%), BRCA2 (11%), 
and other homologous recombination genes, such as 
CDK12 and RAD50.6 BRCA1/2 and other genes in the 
Fanconi anemia (FA)/BRCA pathway play a key role in 
homologous recombination, the main mechanism that 
repairs double-strand DNA breaks. Inherited mutations 
in BRCA1 and BRCA2 account for the majority of famil-
ial ovarian carcinoma,7 but mutations in other members 
of the FA/BRCA family, such as BRIP1, RAD51C, and 
RAD51D, are also associated with a susceptibility to ovar-
ian cancer.8-10 In addition to the familial ovarian cancer 
syndromes, a number of sporadic tumors also are defec-
tive in homologous recombination repair and share the 
phenotype associated with BRCA1/2 cancers, a concept 
known as BRCAness.11 Between 30% and 50% of high-
grade serous ovarian cancers are associated with defects 
in homologous recombination pathways,6,12 and targeting 
homologous recombination deficiency has become one 
of the first genotype-directed therapeutic approaches for 
ovarian cancer. 
Homologous Recombination and PARP 
Inhibition
DNA is constantly subjected to damage, and repair via 
several coordinated pathways is essential to allow cells to 
progress through the cell cycle and complete replication 
without errors.13 DNA damage results in single-strand 
and double-strand breaks, and homologous recombina-
tion is the main mechanism by which the double-strand 
breaks are repaired. The BRCA1/2 genes, among others, 
encode key proteins involved in homologous recombina-
tion. Double-strand DNA breaks can also be repaired 
with nonhomologous end-joining and single-strand 
repair mechanisms, although these are more error-prone 
than homologous recombination.14 Different mecha-
nisms exist for repairing single-strand breaks, including 
base excision repair, nucleotide excision repair, and 
mismatch repair, processes which are modulated by 
poly(adenosine diphosphate-ribose) polymerase (PARP). 
PARP binds to the DNA break site and recruits other 
elements of the DNA repair complex.14 If a cell fails to 
repair single-strand breaks before attempting replication, 
a double-strand break will then form. 
Cells with defective homologous recombination 
pathways must rely on alternative pathways for DNA 
repair in order to survive, thereby providing a potential 
therapeutic target. PARP inhibitors capitalize on this 
concept. The development of PARP inhibitors as a treat-
ment for ovarian cancer was prompted by observations 
that BRCA1/2 gene mutations, which result in homolo-
gous recombination DNA repair deficiency, greatly 
increased the in vitro sensitivity of cancer cells to PARP 
inhibition, exploiting a concept known as synthetic 
lethality.15,16 Synthetic lethality occurs when an otherwise 
innocuous defect in a gene or protein becomes lethal to 
certain cells when combined with another gene or protein 
defect.17 Cells with defective homologous recombina-
tion are dependent on nonhomologous end-joining and 
single-strand DNA repair, and thus are sensitive to PARP 
inhibition. PARP inhibition produces stalled replication 
forks, increasing the number of double-strand breaks and 
leading to genetic chaos and cell death via apoptosis or 
senescence.15,16 BRCA1/2 mutations are not the only ones 
that confer sensitivity to PARP inhibition. In vitro studies 
have demonstrated that deficiencies in other homolo-
gous recombination proteins, such as ATM, CHEK1, 
CHEK2, RAD51D, and CDK12, also confer sensitivity 
to PARP inhibition.8,18,19 Clinical studies have reinforced 
the in vitro concept of BRCA1/2 mutations and PARP 
inhibitor synthetic lethality. Multiple PARP inhibitors are 
in clinical development either as single agents or in com-
bination therapy for the management of ovarian cancer. 
This article, which is the first in a 2-part series, focuses on 
the development of olaparib (Lynparza, AstraZeneca). A 
number of other PARP inhibitors are in development and 
are discussed further in part 2 of this review.
Early Phase 1 and Phase 2 Monotherapy Trials
Olaparib, formerly known as AZD2281, is a small-mol-
ecule, potent oral PARP inhibitor.20 It is the best-studied 
PARP inhibitor to date. The first study of olaparib in 
humans provided clinical evidence for the efficacy of 
PARP inhibitors in cancers associated with BRCA1 or 
BRCA2 mutations.21 This dose escalation study enrolled 
60 patients and was enriched for carriers of BRCA1 and 
BRCA2 mutations. The olaparib dose and schedule were 
increased from 10 mg daily for 2 of every 3 weeks to 600 mg 
twice daily continuously. Reversible dose-limiting toxicity 
was seen in 1 of 8 patients treated with 400 mg twice daily 
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(grade 3 mood alteration and fatigue) and 2 of 5 patients 
receiving 600 mg twice daily (grade 3 somnolence and 
grade 4 thrombocytopenia). A dosage of 200 mg twice 
daily was chosen for the subsequent BRCA1/2-mutated 
expansion cohort. The majority of adverse effects observed 
were grade 1 or 2 and included nausea (32%), fatigue 
(30%), anorexia (12%), and anemia (5%). Pharmacody-
namic analysis confirmed PARP inhibition in surrogate 
tissues (peripheral blood mononuclear cells and plucked 
eyebrow-hair follicles) with the induction of γH2AX 
foci, a marker of double-strand DNA breaks.16 Objective 
antitumor activity was observed only in cancers associ-
ated with the BRCA1/2 mutations.21 Overall, 23 patients 
carrying the BRCA1/2 mutation were treated, 2 of whom 
could not be evaluated for response and 2 of whom had 
tumors not typically associated with BRCA mutations. Of 
the remaining 19 carriers of the BRCA1/2 mutation with 
ovarian, breast, and prostate cancer, 63% had a clinical 
benefit from olaparib treatment with radiologic or tumor-
marker responses or disease stabilization for a period of 4 
months or greater.21 The trial was subsequently expanded 
to include a total of 50 germline BRCA1/2 mutation carri-
ers (BRCA1, 41; BRCA2, 7; BRCA2 variants of uncertain 
significance, 1; strong family history only, 1) with ovar-
ian, primary peritoneal, or fallopian tube carcinoma.22 
The majority of patients were treated within the expan-
sion cohort with 200 mg twice daily (39/50). A total of 
40% of patients had either a partial response or a com-
plete response based on Response Evaluation Criteria In 
Solid Tumors (RECIST), cancer antigen 125 (CA-125) 
responses by Gynecologic Cancer Intergroup (GCIG) 
criteria, or both, with a median duration of response of 
28 weeks in responders.22 The authors noted a significant 
association between platinum-free interval and response 
to olaparib, with an overall clinical benefit rate of 69.2%, 
45.8%, and 23.1% in the platinum-sensitive (defined 
as recurrence ≥6 months after prior platinum therapy), 
platinum-resistant (defined as recurrence <6 months after 
prior platinum therapy), and platinum-refractory groups, 
respectively.22 Despite this, there was no significant dif-
ference in the duration of response to olaparib or time 
to progression observed between patients whose tumors 
were platinum-sensitive, -resistant, or -refractory. The 
data suggest that although there may be some shared 
resistance mechanisms between platinum chemotherapy 
and PARP inhibition, the overlap is not complete because 
antitumor activity for olaparib was observed in patients 
with platinum-refractory disease. 
Although the maximum tolerated dose of olaparib in 
the initial phase 1 study was 400 mg twice daily, maxi-
mal pharmacodynamic activity was observed in tumor 
biopsies and surrogate tissues with doses of 60 mg twice 
daily or greater.21 Furthermore, clinical responses were 
observed at doses of 100 mg twice daily.21 Therefore, a 
multicenter phase 2 study was undertaken to assess the 
efficacy and safety of oral olaparib monotherapy at the 
maximum tolerated dose (400 mg twice daily) and at a 
pharmacodynamically active lower dose (100 mg twice 
daily) for treatment of recurrent ovarian cancer in carri-
ers of BRCA1/2 mutations.23 This study was performed 
in heavily pretreated patients, with a median of 3 previ-
ous chemotherapy regimens (range, 1-16). An objective 
response was observed in 33% of patients in the 400 mg 
twice-daily group and in 13% of those in the 100 mg 
twice-daily group, with a median PFS of 5.8 months 
(95% CI, 2.8-10.6) and 1.9 months (95% CI, 1.8-3.6), 
respectively.23 The majority of toxicity observed was grade 
1 or 2 and similar to the profile seen in the phase 1 study. 
Grade 3 or 4 hematologic toxicity, however, was greater in 
the cohort treated with 400 mg twice daily (neutropenia, 
9%; anemia, 3%).23 Although clinical activity was seen 
in the population treated with 100 mg twice daily, the 
lower dose appeared to be less efficacious than the 400 mg 
twice-daily dose. Furthermore, the authors noted that the 
allocation was not randomized and there was a greater 
proportion of patients with poorer prognostic features in 
the 100-mg cohort.23 Responses were observed in both 
platinum-sensitive and platinum-resistant tumors in the 
400 mg twice-daily cohort, consistent with prior observa-
tions that the mechanisms of resistance to olaparib might 
only partly overlap with those for platinum salts. 
Subsequent phase 2 studies evaluating the role of 
olaparib monotherapy in relapsed ovarian or primary 
peritoneal cancer have shown response rates of between 
31% and 41% in carriers of BRCA1/2 mutations24,25 and 
up to 21% in patients without BRCA1/2 mutations.24 
Study 42, a multicenter phase 2 trial, enrolled 298 patients 
with germline BRCA1/2 mutations and recurrent cancer. 
Inclusion criteria included ovarian cancer resistant to 
prior platinum therapy; breast cancer with 3 prior chemo-
therapy regimens for metastatic disease; pancreatic cancer 
with prior gemcitabine treatment; or prostate cancer with 
progression on hormonal treatment and one systemic 
therapy.25 The study included 193 patients with ovar-
ian cancer. A total of 77% of these patients had BRCA1 
mutations and 23% had BRCA2 mutations. Patients were 
heavily pretreated (mean number of prior regimens, 4.3), 
had received prior platinum therapy, and were considered 
to be platinum-resistant. The patients with ovarian cancer 
experienced a tumor response rate of 31.1% (95% CI, 
24.6%-38.1%) and a rate of stable disease at 8 weeks or 
greater of 40% (95% CI, 33.4%-47.7%). Median PFS 
and overall survival (OS) were 7.0 months and 16.6 
months, respectively, with a median duration of response 
of 225 days.25 On the basis of this study and other data 
from a similar group of women, the US Food and Drug 
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Administration approved olaparib (400 mg twice daily) as 
monotherapy for patients with germline BRCA-mutated 
advanced ovarian cancer who have been treated with 3 or 
more prior lines of chemotherapy.26
Randomized Phase 2 and 3 Trials
The first randomized trial assessing the efficacy of olapa-
rib in relapsed ovarian cancer used pegylated liposomal 
doxorubicin (PLD) in the comparator arm. PLD is 
approved as therapy for relapsed ovarian cancer, with a 
response rate of 20% and a median PFS of 16.1 weeks.27 
This multicenter, open-label phase 2 study included 97 
patients with ovarian cancer that recurred within 12 
months of prior platinum therapy and with confirmed 
germline BRCA1 or BRCA2 mutations. Patients were 
randomly assigned in a 1:1:1 ratio to olaparib 200 mg 
twice daily continuously, olaparib 400 mg twice daily 
continuously, or PLD 50 mg/m2 intravenously every 28 
days.28 Median PFS was 6.5 months (95% CI, 5.5-10.1 
months), 8.8 months (95% CI, 5.4-9.2 months), and 
7.1 months (95% CI, 3.7-10.7 months) for the olaparib 
200 mg, olaparib 400 mg, and PLD groups, respectively. 
There was no statistically significant difference in PFS 
(hazard ratio [HR], 0.88; 95% CI, 0.51-1.56; P=.66) 
for combined olaparib doses vs PLD. Overall response 
rates by RECIST were not significantly different, either 
(25% for olaparib 200 mg, 31% for olaparib 400 mg, 
and 18% for PLD).28 It has been suggested that the 
better-than-expected performance of the comparator 
PLD arm confounded the ability to see a benefit in 
favor of olaparib. One possibility is that patients with 
germline BRCA1/2 mutations derive greater benefit 
from anthracycline-based therapy than do unselected 
patients. This is consistent with a retrospective analysis 
suggesting a potential link between germline BRCA1/2 
mutations and a greater response to PLD.29 In keeping 
with this, a correlation between functional homologous 
recombination deficiency and clinical benefit from the 
use of neoadjuvant anthracycline-based chemotherapy 
in sporadic breast cancer has been observed.30 
This hypothesis is being tested in the SOLO-3 
(Olaparib Treatment in Relapsed Germline Breast 
Cancer Susceptibility Gene [BRCA] Mutated Ovar-
ian Cancer Patients Who Have Progressed at Least 
6 Months After Last Platinum Treatment and Have 
Received at Least 2 Prior Platinum Treatments) phase 3 
trial (NCT02282020). Patients with BRCA1/2-mutated 
ovarian cancer that has progressed at least 6 months after 
platinum therapy and who have received at least 2 prior 
platinum regimens are randomly assigned to physician’s-
choice single-agent nonplatinum chemotherapy or to 
olaparib.
Olaparib as Maintenance Therapy
Emerging data from studies of olaparib have shown anti-
tumor activity in patients with and without BRCA1/2 
mutations. Tumor responses were greatest in women 
with a platinum-sensitive relapse.24 To test this hypothesis 
further, a randomized phase 2 trial was designed to study 
the effect of maintenance olaparib on PFS in all patients 
with high-grade serous ovarian cancer who had responded 
to platinum-based chemotherapy. For the Study 19 trial, 
researchers randomly assigned 265 patients with recur-
rent high-grade ovarian cancer following the completion 
of platinum-based chemotherapy to receive either main-
tenance olaparib or placebo.31 A minimum of 2 prior 
platinum-containing regimens were required for study 
entry, and patients received a median of 3 regimens in 
both arms. At the time of study entry, more than 62% of 
patients in both study arms had unknown BRCA1/2 muta-
tion status. A total of 22.8% of patients in the olaparib 
arm and 21.7% of those in the placebo arm, respectively, 
had known germline mutations in BRCA1/2. PFS after the 
completion of chemotherapy was significantly longer with 
olaparib than with placebo (median, 8.4 vs 4.8 months; 
HR for progression or death, 0.35; 95% CI, 0.25-0.49; 
P<.001).31 A retrospective analysis to determine tumor and 
germline BRCA status was undertaken so that a preplanned 
retrospective analysis of outcome by BRCA status could 
be performed. Data were available on 96% of patients, 
and 51.3% had either a germline BRCA1/2 mutation or a 
BRCA mutation in the tumor. A greater benefit was seen 
in patients whose tumors harbored BRCA1/2 mutations 
(either germline or somatic), with PFS extended from 4.3 
to 11.2 months (HR, 0.18; 95% CI, 0.10-0.31).32 Impor-
tantly, patients with BRCA wild-type tumors also derived 
a benefit from olaparib maintenance. The magnitude of 
benefit between the groups was smaller, however, at 7.4 vs 
5.5 months (HR, 0.54; 95% CI, 0.34-0.85), confirming a 
sensitive BRCA1/2–wild-type group. 
The median time to first subsequent therapy was 
determined in a secondary analysis. This provides clini-
cally relevant information about the time interval between 
progression and the start of further treatment of cancer. 
Patients’ treatment was not unblinded on progression. In 
the overall population, the time to initiation of further 
treatment was significantly longer in the olaparib group 
than with placebo (13.4 vs 6.7 months; HR, 0.40; 95% CI, 
0.30-0.52) and in both the BRCA1/2-mutated population 
(15.6 vs 6.5 months; HR, 0.33; 95% CI, 0.22-0.50) and 
wild-type BRCA subgroups (12.9 vs 6.9 months; HR, 0.45; 
95% CI, 0.30-0.67).32 Olaparib also extended the time to 
second subsequent therapy in both BRCA1/2-mutated and 
BRCA1/2–wild-type tumors,32 suggesting that olaparib 
treatment did not alter subsequent response to platinum 
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or other therapies, a conclusion supported by subsequent 
reports.33 Despite improvements in PFS and time to sub-
sequent therapy, no statistically significant improvement in 
OS was observed (77% maturity) between the groups (HR, 
0.73; 95% CI, 0.55-0.96, P value, not significant), with 
an increased benefit observed for patients with mutated 
BRCA1/2 (HR, 0.62; 95% CI, 0.41-0.94) compared with 
wild-type BRCA1/2 (HR, 0.83; 95% CI, 0.55-1.24).34 
The failure of PFS to translate into an OS benefit is likely 
multifactorial. First, a significant number of patients 
with a BRCA1/2 mutation who received placebo (14/62; 
23%) went on to receive a PARP inhibitor after progres-
sion. Secondly, the study was not designed to evaluate OS 
with statistical significance. Importantly, 13% of the total 
population (15% of the BRCA1/2-mutated population) 
remained on olaparib for more than 5 years.34 In terms of 
toxicity, the olaparib group reported more nausea (68% 
vs 35%), fatigue (49% vs 38%), vomiting (32% vs 14%), 
and anemia (17% vs 5%), although the majority of adverse 
events were grade 1 or 2.31
Based on these data, the European Medicines Agency 
approved olaparib as maintenance treatment in women 
with platinum-sensitive, relapsed BRCA1/2-mutated 
(germline and/or somatic) ovarian cancer who have sus-
tained either a complete or partial response to platinum-
based chemotherapy.35 Furthermore, these data have led 
to an additional phase 3 maintenance study of olaparib vs 
placebo after first-line platinum chemotherapy; SOLO-1 
(Olaparib Maintenance Monotherapy in Patients With 
BRCA Mutated Ovarian Cancer Following First Line 
Platinum Based Chemotherapy; NCT01844986), the 
results of which are awaited.  
Olaparib Combination Therapy 
It is still unclear whether olaparib is best deployed as a 
single agent, combined with chemotherapy, or as main-
tenance following platinum chemotherapy. Combination 
with chemotherapy is an attractive concept because it 
exploits the potential synergy between PARP inhibition 
and DNA-damaging cytotoxic agents. The clinical devel-
opment of olaparib has included many phase 1 trials in 
which it is combined with chemotherapy. This often leads 
to exacerbation of toxicity—most often myelosuppres-
sion—and subsequent dose reductions. For example, the 
combination of olaparib plus topotecan was associated 
with significant dose-limiting hematologic adverse events, 
resulting in a subtherapeutic maximum tolerated dose.36 
Likewise, the combination of cisplatin and olaparib was 
considered intolerable owing to hematologic toxicity,37 and 
the combination of paclitaxel and olaparib was compli-
cated by significant clinical interaction and greater-than-
anticipated neutropenia despite secondary  prophylaxis.38 
The combination of PLD with either continuous or 
intermittent olaparib yielded an overall response rate of 
50% in patients with recurrent ovarian cancer (≤3 prior 
chemotherapy regimens),39 with the majority of responses 
observed in patients with germline BRCA1/2 mutations 
(11/13 responders). However, grade 3 to 4 toxicity was 
observed in 61% of patients, with 1 possible treatment-
related death from pneumonia/pneumonitis.39 These 
results suggest that although additive or even synergistic 
chemopotentiation effects may exist in vitro, there is not a 
wide therapeutic index between normal tissue and tumor 
tissue. Therefore, delivering these combinations is prob-
lematic without dosing or scheduling modifications. For 
example, when combining olaparib with carboplatin and 
paclitaxel, continuous olaparib dosing exacerbated hema-
tologic toxicities and led to schedule delays.40 Tolerability 
improved with intermittent olaparib and reduced-dose 
carboplatin (area under the curve [AUC], 4 mg/mL/min), 
prompting a randomized phase 2 study.41 
Oza and colleagues randomly assigned 162 patients 
with recurrent platinum-sensitive ovarian cancer to 
receive either olaparib (200 mg twice daily, administered 
orally on days 1-10 of each 21-day cycle) plus pacli-
taxel (175  mg/m2, administered intravenously on day 
1) and carboplatin (AUC, 4 mg/mL/min administered 
intravenously on day 1), then olaparib monotherapy 
(400 mg twice daily, given continuously) until progres-
sion, or paclitaxel (175 mg/m2 on day 1) and carbo-
platin (AUC, 6 mg/mL/min on day 1), then no further 
treatment.41 The BRCA1/2 mutation status was known 
for 107 patients (either at baseline or determined retro-
spectively): 41 (38%) of 107 had a BRCA1/2 mutation 
(20 in the olaparib/chemotherapy group and 21 in the 
chemotherapy-alone group). The addition of olaparib to 
chemotherapy significantly improved the median PFS 
(12.2 vs 9.6 months with chemotherapy alone; HR, 
0.51; 95% CI, 0.34-0.77). In an exploratory analysis, 
the benefit was greatest in the BRCA1/2-mutated group 
(median PFS not reached in the olaparib group vs 9.7 
months with chemotherapy alone; HR, 0.21; 95% CI, 
0.08-0.55). Overall survival did not differ significantly 
between groups for either the overall population (33.8 
months for olaparib/chemotherapy vs 37.6 months with 
chemotherapy alone; HR, 1.17; 95% CI, 0.79-1.73) 
or the BRCA1/2-mutated population (not reached with 
olaparib/chemotherapy vs 39.2 months with chemother-
apy alone; HR, 1.28, 95% CI, 0.39-4.18). A significant 
benefit in favor of olaparib/chemotherapy was noted in 
time to first subsequent therapy (HR, 0.60; 95% CI, 
0.42-0.86) but not time to second therapy (HR, 0.83; 
95% CI, 0.57-1.20).41 Adverse events were greater in the 
olaparib/chemotherapy group and were mostly mild or 
moderate: nausea (69% vs 57%), neutropenia (49% vs 
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39%), diarrhea (42% vs 27%), headache (33% vs 9%), 
and peripheral neuropathy (31% vs 19%). The most 
common grade 3 or higher adverse events during the 
combination phase were neutropenia (43% vs 35%) and 
anemia (9% vs 7%). The rate of serious adverse events was 
similar in both arms (15% with olaparib/chemotherapy 
and 21% with chemotherapy alone). It was noted that 
the PFS benefits occurred despite the lower carboplatin 
dose (AUC, 4 mg/mL/min),40 suggesting that olaparib 
might provide an additive effect or potentiate the cyto-
toxic effect of the lower carboplatin dose. However, the 
authors noted that although the study was not designed 
to measure the contribution of each treatment phase, 
the late separation of the PFS curves suggested that the 
maintenance phase was probably the key contributor to 
the improvement in PFS. They concluded that the com-
bination of olaparib and chemotherapy in this context 
does not provide an additional advantage over olaparib 
alone as maintenance therapy.41
Perhaps more promising combinations are those of 
olaparib with other molecularly targeted agents, owing to 
the potential synergy with other signaling pathways and 
lack of overlapping toxicity profiles. Several randomized 
trials have shown efficacy in ovarian cancer for antiangio-
genic agents in combination with platinum therapy in 
first-line and salvage settings.42-44 Preclinical studies have 
demonstrated the additive effect of antiangiogenesis and 
PARP inhibition, given that hypoxia leads to downregu-
lation of homologous recombination repair proteins and 
enhanced PARP inhibitor sensitivity.45-47 
A dose-finding phase 1 trial that combined cediranib 
(the oral ATP-competitive vascular endothelial growth 
factor receptor inhibitor) with olaparib demonstrated 
activity in recurrent ovarian cancer, with an objective 
response rate of 44%.48 This finding prompted a random-
ized phase 2 study, the results of which were reported in 
2014. Liu and colleagues randomly assigned patients with 
relapsed high-grade serous or endometrioid ovarian can-
cers to receive olaparib (400 mg twice daily, n=46) or the 
combination of olaparib and cediranib (cediranib 30 mg 
daily and olaparib capsules 200 mg twice daily, n=44).49 
BRCA1/2 mutations were present in 52% of patients in 
both treatment arms. Median PFS was significantly longer 
in the combination arm than with olaparib alone (17.7 vs 
9.0 months; HR, 0.42; 95% CI, 0.23-0.76), as was objec-
tive response rate (79.6% vs 47.8%; odds ratio, 4.24; 95% 
CI, 1.53-12.22). An exploratory analysis was performed 
in BRCA-mutated and BRCA–wild-type or unknown 
subsets, although the results should be interpreted with 
caution owing to the small numbers in each subset. 
Greater activity for the combination arm was noted in 
both populations. In the BRCA1/2–wild-type/unknown 
group, median PFS was 16.5 vs 5.7 months (HR, 0.32; 
95% CI, 0.14-0.74). In the BRCA1/2-mutant group, 
median PFS was 19.4 vs 16.5 months (HR, 0.55; 95% 
CI, 0.24-1.27). This trial did not include a single-agent 
cediranib arm; however, phase 2 single-agent studies have 
suggested a median PFS of approximately 5 months with 
cediranib alone.50,51 These results suggest that the combi-
nation of olaparib and cediranib could be synergistic and 
have greater activity than either agent alone in patients 
with platinum-sensitive, high-grade serous ovarian can-
cers. The magnitude of benefit observed for combination 
therapy was greater in the absence of BRCA1/2 mutation; 
one possible explanation is that greater synergy is observed 
with more proficient homologous recombination. 
Whether the combination of olaparib and cediranib 
is better than standard chemotherapy for recurrent ovarian 
cancer is currently being evaluated in 2 randomized phase 
3 trials for both platinum-sensitive (NCT02446600) and 
platinum-resistant disease (NCT025022660, Table  1). 
Furthermore, whether olaparib and cediranib mainte-
nance therapy is superior to cediranib therapy alone, 
following platinum-based chemotherapy with cediranib 
Table 1. Ongoing Randomized Phase 3 Olaparib Combination Studies
NCT Trial Number  
or Trial Name 
Combination Platinum 
Status
Inclusion Criteria
NCT02477644  
(PAOLA-1)
Olaparib or placebo in combination with platinum/
taxane and bevacizumab and as maintenance therapy 
First-line 
treatment 
HGSOC/endometrioid, stage IIIb/
IV
NCT02446600 Olaparib and cediranib or platinum-doublet 
chemotherapy 
Platinum-
sensitive 
HGSOC/endometrioid or gBRCA 
and any high-grade histology
NCT02502266 Olaparib and cediranib or chemotherapy Platinum-
resistant 
HGSOC/endometrioid or gBRCA 
and any high-grade histology
ICON9 Olaparib with cediranib vs cediranib and placebo 
as maintenance therapy following platinum-based 
chemotherapy with cediranib
Platinum-
sensitive
HGOC
gBRCA1/2, germline BRCA1/2 mutation; HGOC, high-grade ovarian cancer; HGSOC, high-grade serous ovarian, fallopian tube, or primary peritoneal cancer; ICON9, 
Randomised Trial of Cediranib and Olaparib Maintenance in Patients with Relapsed Platinum Sensitive Ovarian Cancer; NCT, National Clinical Trial; PAOLA-1, 
Platine, Avastin and Olaparib in 1st Line.
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for the first platinum-sensitive recurrence will be evalu-
ated in the ICON9 study (Randomised Trial of Cediranib 
and Olaparib Maintenance in Patients with Relapsed 
Platinum Sensitive Ovarian Cancer). In the first-line set-
ting, the PAOLA-1 trial (Platine, Avastin and Olaparib 
in 1st Line; NCT02477644) is investigating the addition 
of olaparib to bevacizumab (Avastin, Genentech) main-
tenance in women receiving carboplatin, paclitaxel, and 
bevacizumab (Table 1).
Early-Phase Olaparib Combination Studies
Activation of the phosphoinositide 3-kinase (PI3K) and 
RAS signaling pathways is common in high-grade serous 
ovarian cancer, occurring in up to 45% of patients.6 Pre-
clinical studies have suggested that inhibition of the PI3K 
pathway results in genomic instability, accompanied by a 
concomitant reduction in the expression of BRCA1 and 
BRCA2 and a reduction in the cellular capacity to con-
duct homologous recombination. The result is cells that 
are sensitized to olaparib52; an in vivo study53 has shown 
suppression of tumor growth with the combination of 
olaparib and the PI3K inhibitor BKM120. A number of 
early-phase trials are currently underway that are exam-
ining the combination of olaparib with inhibitors of the 
PI3K signaling pathway (Table 2), including the PI3K 
inhibitor BKM120 (NCT01623349), the AKT inhibitor 
AZD5363 (NCT02338622), and the dual mammalian 
target of rapamycin complex 1/2 (mTORC1/2) inhibitor 
AZD2014 (NCT02208375). 
Immune checkpoint blockade using antibodies to 
cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4, 
CD152) or programmed death protein 1 (PD-1, CD279) 
have demonstrated sustained clinical efficacy in melanoma 
and other solid tumors. Emerging evidence suggests that 
genetically heterogeneous tumors with greater mutational 
burden are more likely to respond to checkpoint blockade.54 
Although ovarian cancers have been considered relatively 
resistant to anti–CTLA-4 blockade, there is evidence that 
a subset of ovarian cancers associated with germline muta-
tions in BRCA1/2 genes may be more immunogenic, and 
therefore more vulnerable to checkpoint blockade.55-57 This 
is supported in vitro by BRCA1-mutant human cell lines 
and by animal-based studies in which a CTLA-4 antibody, 
synergized therapeutically with the investigational PARP 
inhibitor veliparib, resulted in immune-mediated tumor 
clearance and long-term survival in a majority of animals.58 
Early-phase combination studies with olaparib and both 
PD-1/programmed death-ligand 1 (PD-L1) and CTLA-4 
antibodies are underway (Table 2) in both BRCA1/2-mutant 
and wild-type patients. 
Expanding the Scope for PARP Inhibition
Dramatic responses to PARP inhibition have been 
observed in germline-associated BRCA-mutated tumors. 
However, significant challenges exist in identifying other 
patients with homologous recombination deficiency who 
are also likely to derive benefit from PARP inhibitors. 
BRCA1/2 function may also be disrupted by somatic 
mutations or epigenetic silencing. For example, of the 
103 cases with BRCA dysfunction identified in the 
Table 2. Ongoing Early-Phase Olaparib Combination Studies
NCT Trial 
Number 
Phase Combination Inclusion Criteria BRCA Status
NCT02208375 1/2 AZD2014 (mTORC1/2) 
AZD5363 (AKT)
HGSOC Mutant and WT
Endometrial
TN breast
NCT02338622 1 AZD5363 (AKT) Part A, any solid tumor Mutant or PI3K/AKT activated
Part B, BRCA-mutated or PI3K/
AKT hyperactivated
NCT01623349 1 BKM120 (PI3K) or 
BYL719 (PI3K)
HGSOC
TN breast
Mutant and WT
NCT02571725 1/2 Tremelimumab (CTLA-4) EOC gBRCA1/2
NCT02484404 1/2 MEDI4376 (PD-L1) Any solid tumor or recurrent 
ovarian cancer
Mutant and WT
NCT02485990 1/2 Tremelimumab (CTLA-4) HGSOC Mutant and WT
CTLA-4, cytotoxic T-lymphocyte–associated antigen 4; EOC, epithelial ovarian, fallopian tube, or primary peritoneal carcinoma; gBRCA1/2, germline BRCA1/2 
mutation; HGSOC, high-grade serous ovarian, fallopian tube, or primary peritoneal cancer; mTORC1/2, mammalian target of rapamycin complex 1/2; NCT, National 
Clinical Trial; PD-L1, programmed death-ligand 1; PI3K, phosphoinositide 3-kinase; TN, triple-negative; WT, wild-type.
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genomic analysis of high-grade serous ovarian cancer by 
The Cancer Genome Atlas (TCGA), 34 cases were associ-
ated with BRCA1 silencing via DNA hypermethylation.6 
Interestingly, data from TCGA and others have failed to 
correlate BRCA1 hypermethylation with either platinum 
sensitivity or improved survival,6 suggesting that epigen-
etic BRCA1 downregulation may have less of an effect 
on homologous recombination and PARP inhibition than 
BRCA1-inactivating mutations. Somatic BRCA1/2 muta-
tions are also common, present in 19 of the 103 cases 
from TCGA.6 Similarly, 18 (14%) of 136 patients with 
a BRCA1/2 mutation in study 19 had tumor BRCA1/2 
mutations of somatic origin.32 It will be important to 
identify patients who harbor sporadic somatic BRCA1/2 
mutations or other homologous recombination-deficient 
tumors and who may benefit from PARP inhibitor 
therapy. This is discussed further in part 2 of this review. 
Conclusions and Future Directions
The introduction of olaparib and other PARP inhibitors 
represents one of the most promising genotype-directed 
therapies, which are destined to change the management 
of BRCA-associated ovarian cancer. However, a number 
of challenges still remain. 
Firstly, it is uncertain how olaparib should be incor-
porated into the clinical management of both BRCA1/2-
associated and sporadic ovarian cancers. It has yet to be 
established whether olaparib should be introduced before 
or after platinum therapy, in the first-line or relapsed 
setting, or as maintenance therapy. Secondly, it is not 
clear whether, as maintenance therapy, additional benefit 
would be obtained if olaparib (or indeed, another PARP 
inhibitor) maintenance were to be reinstituted at each 
chemotherapy-induced remission. Another challenge is 
determining whether combination therapy is superior 
to single-agent olaparib use. Owing to overlapping tox-
icities, particularly myelosuppression, work is required to 
define the optimal schedules for the combination of che-
motherapy and olaparib. Furthermore, it is unclear where 
combination treatment with vascular endothelial growth 
factor and other signaling inhibitors is best employed. In 
addition, the role of olaparib in platinum-resistant disease 
requires clarity. Finally, it is not yet known whether clini-
cal differences exist between PARP inhibitors in terms 
of efficacy and toxicity, or indeed whether there is a role 
for rechallenge with a different PARP inhibitor following 
progression on another. 
Several phase 3 trials are underway to address many 
of the above questions, and it is hoped that the use of 
olaparib and other PARP inhibitors can be optimized to 
maximize PFS—and ultimately, OS—for patients with 
ovarian cancer. 
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